TrialThe oncologist2026

Phase II study of olaparib plus durvalumab in EGFR-mutant NSCLC transformed to small cell lung cancer.

Chirayu Mohindroo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.